Budesonide Oral Suspension Improves Dysphagia in Eosinophilic Esophagitis
Budesonide oral suspension was associated with improvements in dysphagia in patients with eosinophilic esophagitis.
Eosinophilic Esophagitis
Benralizumab Receives Orphan Drug Status for Eosinophilic Esophagitis
The FDA has granted Orphan Drug designation to benralizumab for the treatment of eosinophilic esophagitis.
Role of Environmental Risk Factors in Eosinophilic Esophagitis
Potential risk factors for eosinophilic esophagitis include antibiotic use in infancy and behaviors such as smoking and alcohol intake.
Next post in Allergies
